Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.65 |
| ▸ | MAPT | P10636 | 7/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | TP53 | P04637 | 5/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | EGFR | P00533 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10620481 | 0.93 | SMN1; SMN2 (0.76) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL10026577 | 0.90 | MAPT (0.81) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL12892701 | 0.88 | RAB9A (0.81) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL14341461 | 0.84 | MEN1 (0.56) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL18326541 | 0.83 | EGFR (0.60) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL12692500 | 0.82 | SMN1; SMN2 (0.86) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL10624596 | 0.81 | EGFR (0.77) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL10001908 | 0.80 | SMN1; SMN2 (0.62) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| SCHEMBL13640727 | 0.80 | KDM4E (0.67) | MEN1KMT2AMAPTSMN1; SMN2HPGD | |
| Genistein SCHEMBL554056 | 0.79 | MAPT (1.00) | MEN1KMT2AMAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | NORTHWESTERN UNIVERSITY (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283313-A1 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS | MAPK4, MAP4K4, MAP3K4 | MEN1 302/4885KMT2A 772/4885MAPT 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.